Hello, Guest!
  • Sunday, November 24, 2024

Leidos to Support DTRA Anti-Biological Weapons Program


TYSONS CORNER, VA, Jan. 31, 2017 ” The Defense Threat Reduction Agency has awarded Leidos (NYSE: LDOS) a $35.9 million contract to support an initiative that aims to prevent the development of new biological weapons, ExecutiveBiz reported Monday.

Leidos will provide technical and scientific services to support various projects under the Cooperative Biological Engagement program potentially through Jan. 30, 2022, the Defense Department said Friday.

About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com

Contact:
David Smith
(703) 226-7002
[email protected]

Video of the Day

Related Articles

Leidos Books $197M CMS IT Support Task Order; Liz Porter Quoted Contract Awards

Leidos Books $197M CMS IT Support Task Order; Liz Porter Quoted

Leidos (NYSE: LDOS) will help the Centers for Medicare and Medicaid Services implement new information technology processes as part of a $197 million task order. The award has a firm-fixed-price, time and materials structure and covers support for the agency’s IT office and infrastructure and user support team, Leidos said Monday. CMS tasked the company

Leidos Receives $60M Federal Highway Administration Policy Support BPA; Fran Hill Quoted Contract Awards

Leidos Receives $60M Federal Highway Administration Policy Support BPA; Fran Hill Quoted

Leidos (NYSE: LDOS) will provide technical and program support to the Federal Highway Administration’s policy and governmental affairs office under a potential five-year, $60 million blanket purchase agreement with the Department of Transportation. The company said Tuesday the multiple-award BPA has a base performance period of five years and an option term of six months

Leidos Logs 4% Q2 Revenue Growth, Maintains 2022 Guidance; Roger Krone Cites Business Development Momentum Financial Reports

Leidos Logs 4% Q2 Revenue Growth, Maintains 2022 Guidance; Roger Krone Cites Business Development Momentum

Leidos (NYSE: LDOS) recorded fiscal 2022 second quarter revenue of $3.60 billion, up 4 percent from the same period a year ago. The Reston, Virginia-based company said net income for the quarter rose to $172 million or $1.24 per share and total backlog as of June 30 was $34.7 billion with $7.5 billion funded. All